ReviewFrontiers in immunology2026
Vunakizumab-induced severe ulcerative colitis during treatment of psoriatic arthritis: a case report and literature review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Interleukin-17A (IL-17A) inhibitors are effective therapies for psoriasis (PsO) and psoriatic arthritis (PsA), yet they may induce or exacerbate inflammatory bowel disease (IBD). Vunakizumab is a novel humanized anti-IL-17A monoclonal antibody approved in China in 2024; post-marketing real-world data on its gastrointestinal safety profile remain limited. Case presentation: We report a 54-year-old male PsA patient who developed acute severe ulcerative colitis (UC) approximately one week after the third injection of vunakizumab, representing the first reported case of vunakizumab-associated IBD in the literature. The patient exhibited marked hepatic enzyme elevation (alanine aminotransferase [ALT] 213 U/L, aspartate aminotransferase [AST] 189 U/L), representing one of the most significant liver injuries reported in this context. The Naranjo Adverse Drug Reaction Probability Scale score was 7 ("probable"). Vunakizumab was immediately discontinued; intravenous methylprednisolone 60 mg/day was administered to induce remission. Following acute-phase control, the patient was switched to guselkumab (an anti-IL-23p19 monoclonal antibody) for maintenance therapy, achieving dual remission of intestinal and articular manifestations. Conclusion: Vunakizumab can induce severe UC. As a newly approved IL-17A inhibitor in China, early post-marketing safety surveillance should remain vigilant for IBD risk. The underlying mechanism may involve disruption of the intestinal epithelial barrier and compensatory upregulation of IL-23 following IL-17A blockade. The early treatment period (within the first 3 months) represents a high-risk window. Upon diagnosis, immediate drug withdrawal, corticosteroid-induced remission, and prioritized conversion to an IL-23 inhibitor (such as guselkumab) may be considered as a potential option to achieve dual control of intestinal, skin, and joint disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.